The Need for Standardized Metrics to Drive Decision-making During the COVID-19 Pandemic

J Matthew Austin, PhD1,2*, Allen Kachalia, MD, JD1,3

1Johns Hopkins Armstrong Institute for Patient Safety and Quality, Johns Hopkins Medicine, Baltimore, Maryland; 2Department of Anesthesiology and Critical Care Medicine, Johns Hopkins Medicine, Baltimore, Maryland; 3Department of Medicine, Johns Hopkins Medicine, Baltimore, Maryland.

The rapid onset of the novel coronavirus disease 2019 (COVID-19) pandemic forced the US healthcare system to scramble to prepare for a health crisis with many unknowns. Early on, it was unclear exactly how the virus was transmitted, how many people would fall ill or how ill they would get, what treatments would be most efficacious, and what resources were needed to care for patients. Given the short window the healthcare system had to prepare, many initial and important decisions were made quickly and often at a local level, with limited coordination and standardization across localities and organizations. These decisions included what services could be offered, how best to allocate potentially scarce resources (such as personal protective equipment and ventilators), and how much surge capacity to build. In short, many of the early decisions about the pandemic were understandably varied, and the lack of standardized metrics to help guide decision-making did not help the situation.

CHALLENGES WITH MANAGING THE PANDEMIC WITHOUT STANDARDIZED METRICS

Unfortunately, as the COVID-19 pandemic continues, there has been insufficient movement toward standardizing definitions for many key measures needed to manage the public health response. Even small differences in definitions can have important implications for decision-making. For example, public health officials have recommended communities achieve a positivity rate of 5% or lower for 14 straight days before easing virus-related restrictions. In Maryland, two different entities are calculating positivity rates for the state using different methodologies and producing different results, which can have significant public health and economic implications for the state. Johns Hopkins University’s Resource Center calculates the positivity rate by comparing the number of people who tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to all people who were tested. This method consistently produces a positivity rate for Maryland above the 5% threshold. In contrast, the state of Maryland calculates the positivity rate by comparing the number of positive tests for SARS-CoV-2 to the number of tests conducted, even if the same person had multiple tests (unless the tests are performed the same day at the same location). This method consistently produces a positivity rate for Maryland below the 5% threshold.

THE POLITICIZATION OF THE DATA

The lack of standardized definitions leads not only to debate and confusion over what steps to take next, but also opens the door to politicization of pandemic data. This is readily apparent when considering mortality due to COVID-19. For example, different states use different definitions for COVID-19 mortality. Alabama defines COVID-19 mortality by only including patients who tested positive for the SARS-CoV-2 virus and the cause of death was attributed to COVID-19. In contrast, Colorado’s COVID-19 mortality definition includes those patients who are believed to have died of COVID-19, but does not require confirmation of SARS-CoV-2 infection by a positive test. Further compounding the challenge, some politicians reference the COVID-19 mortality rate as a comparison of those who died from COVID-19 with those who were sick with COVID-19, reflecting the success rate of treating patients with COVID-19, an area in which the United States has done relatively well compared with other countries. This definition of the mortality rate suits a narrative of successful pandemic management. However, many public health officials suggest the COVID-19 mortality rate should be defined by comparing the number of deaths from COVID-19 as a percentage of the population, which reflects the percentage of the population dying from the disease. In this regard, the United States has not done as well relative to other countries. These different definitions highlight how the United States lacks a standardized way to compare its performance across states and with other countries, even on a straightforward measure like mortality.

CURRENT METRICS THAT NEED STANDARDIZATION

The lack of clarity on, and politicization of, pandemic data demonstrate the need to take stock of what metrics require standardization to help public health officials and health system leaders manage the pandemic response moving forward. The Table provides examples of currently used metrics that would benefit from better standardization to inform decision-making.
TABLE. Examples of Metrics Requiring Standardized Definitions to Manage the COVID-19 Pandemic Response

<table>
<thead>
<tr>
<th>Metric</th>
<th>Open issues that need standardization</th>
<th>Rationale for why this metric is important to standardize</th>
</tr>
</thead>
<tbody>
<tr>
<td>7-day moving average of the incidence rate of SARS-CoV-2 RNA-test positive patients per 100,000 population within a defined geographic area</td>
<td>Should case counts reflect the day the test was performed or the day the test was resulted? Or should they be reported both ways?</td>
<td>Helps determine whether the virus spread is growing or slowing in a community; informs resource planning and reopening decisions</td>
</tr>
<tr>
<td>Cumulative percentage of a defined population that has tested positive for SARS-CoV-2</td>
<td>Should case counts include antigen (RNA) tests only or also include antibody (Ab) tests? Which tests should qualif as negative or positive, given the variation in test performance? How to ensure that figures do not double count those with multiple positive tests (eg, RNA + Ab)</td>
<td>Helps determine the cumulative exposure in a community; informs resource planning and reopening decisions</td>
</tr>
<tr>
<td>Percentage of patients who test positive for SARS-CoV-2</td>
<td>RNA tests provide data for tracking acute infections; both tests allow for tracking case counts over time</td>
<td>RNA tests provide data for tracking acute infections; both tests allow for tracking case counts over time</td>
</tr>
<tr>
<td>Percentage of SARS-CoV-2 RNA tests that return a positive result (test positivity rate)</td>
<td>Should the calculation be based on the day the test was completed or the day the test was resulted? Which tests should qualify as negative or positive, given the variation in test performance? Should the calculation be based on the number of unique persons tested or the number of tests?</td>
<td>From a public health standpoint, helps officials understand how quickly the virus is spreading; helps answer the question if whether the number of positive cases is the result of more testing or the greater spread of the virus; it also helps hospitals understand the positivity rate of admitted patients and patients who will be undergoing surgery</td>
</tr>
<tr>
<td>Average hospital length of stay for patients with COVID-19 disease</td>
<td>Which types of patients should be included in this calculation—those with an RNA-positive test, those with a positive Ab test, and/or those with a clinical diagnosis?</td>
<td>Allows public health officials and hospitals to model the number of intensive care unit (ICU) and non-ICU beds that will be needed to house patients; it would also allow nursing homes and home health agencies to forecast future demand for their services</td>
</tr>
<tr>
<td>COVID-19 mortality rate</td>
<td>Which cases should be included in the numerator: patients who had a positive RNA test for the virus, patients who had a positive RNA or Ab test for the virus, and/or patients who have had symptoms of the disease, but a negative test?</td>
<td>Provides an understanding of how fatal the disease is</td>
</tr>
<tr>
<td>Percentage of patients who test positive for SARS-CoV-2 but did not develop COVID-19 symptoms</td>
<td>How to ensure that case counts do not double count those with multiple positive tests (eg, RNA + Ab)? Which tests should qualify as negative or positive, given the variation in test performance?</td>
<td>Helps public health officials better understand the risk of spread of the disease</td>
</tr>
</tbody>
</table>

Abbreviations: Ab, antibody; COVID-19, coronavirus disease 2019; ICU, intensive care unit; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

across a broad range of settings, including public health, hospitals, physician clinics, and nursing homes. For example, a commonly referenced metric during the pandemic has been a moving average of the incidence rate of positive COVID-19 cases in a defined geographic area (eg, a state). This data point is helpful to healthcare delivery organizations for understanding the change in COVID-19 cases in their cities and states, which can inform planning on whether or not to continue elective surgeries or how many beds need to be kept in reserve status for a potential surge of hospitalizations. But there has not been a consensus around whether the reporting of COVID-19 positive tests should reflect the day the test was performed or the day the test results were available. The day the test results were available can be influenced by lengthy or uneven turnaround times for the results (eg, backlogs in labs) and can paint a false picture of trends with the virus.

As another example, knowing the percentage of the population that has tested positive for COVID-19 can help inform both resource planning and reopening decisions. But there has been variation in whether counts of positive COVID-19 tests should only include antigen tests, or antibody tests as well. This exact question played out when the Centers for Disease Control and Prevention (CDC) made decisions that differed from those of many states about whether to include antibody tests in their publicly announced COVID-19 testing numbers, perhaps undermining public confidence in the reported data.

MOVING FORWARD WITH STANDARDIZING DEFINITIONS

To capture currently unstandardized metrics with broad applicability, the United States should form a consensus task force to identify and define metrics and, over time, refine them based on current science and public health priorities. The task force would require a mix of individuals with various skill sets, such as expertise in infectious diseases and epidemiology, healthcare operations, statistics, performance measurement, and public health. The US Department of Health and Human Services is likely the appropriate sponsor, with representation from the National Institutes of Health, the CDC, and the Agency for Healthcare Research and Quality, in partnership with national provider and public health group representatives.
Once standardized definitions for metrics have been agreed upon, the metric definitions will need to be made readily available to the public and healthcare organizations. Standardization will permit collection of electronic health records for quick calculation and review, with an output of dashboards for reporting. It would also prevent every public health and healthcare delivery organization from having to define its own metrics, freeing them up to focus on planning. Several metrics already have standard definitions, and those metrics have proven useful for decision-making. For example, there is agreement that the turnaround time for a SARS-CoV-2 test is measured by the difference in time between when the test was performed and when the test results were available. This standard definition allows for performance comparisons across different laboratories within the same service area and comparisons across different regions of the country. Once the metrics are standardized, public health leaders and healthcare organizations can use variation in performance and outcomes to identify leading indicators for planning.

CONCLUSION

Amid the COVID-19 pandemic, the US healthcare system finds itself in a state of managing uncertainty for a prolonged period of time. The unprecedented nature of this crisis means that best practices will not always be clear. Providing access to clearly defined, standardized metrics will be essential to public health officials and healthcare organization leaders’ ability to manage through this pandemic. The risk of not moving in this direction means forcing leaders to make decisions without the best information available. Good data will be essential to guiding the US healthcare system through this extraordinary crisis.

Disclosures: The authors reported no conflicts of interest.

References